Discovery and structural optimization of pyrazole derivatives as novel inhibitors of Cdc25B

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 9, 2010, Pages 2876-2879

  Chen, Hai Jun ^a   Liu, Yong ^a   Wang, Li Na ^a   Shen, Qiang ^a   Li, Jia ^a   Nan, Fa Jun ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cdc25B inhibitor; Pyrazole derivatives; Structural optimization

Indexed keywords

3,5 DIACYL PYRAZOLE DERIVATIVE; BN 82685; MALEIMIDE; NSC 663284; PROTEIN TYROSINE PHOSPHATASE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CYCLOADDITION; DRUG HYDROLYSIS; DRUG STRUCTURE; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

ANTINEOPLASTIC AGENTS; CDC25 PHOSPHATASES; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; KINETICS; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 77950860029     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.040     Document Type: Article

References (31)

1. Nilsson I., and Hoffmann I. Prog. Cell Cycle Res. 4 (2000) 107
2. Galaktionov K., and Beach D. Cell 67 (1991) 1181
3. Sadhu K., Reed S.I., Richardson H., and Russell P. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 5139
4. Nagata A., Igarashi M., Jinno S., Suto K., and Okayama H. New Biol. 3 (1991) 959
5. Takemasa I., Yamamoto H., Sekimoto M., Ohue M., Noura S., Miyake Y., Matsumoto T., Aihara T., Tomita N., Tamaki Y., Sakita I., Kikkawa N., Matsuura N., Shiozaki H., and Monden M. Cancer Res. 60 (2000) 3043
6. Kristjansdottir K., and Rudolph J. Chem. Biol. 11 (2004) 1043
7. Lazo J.S., Aslan D.C., Southwick E.C., Cooley K.A., Ducruet A.P., Joo B., Vogt A., and Wipf P. J. Med. Chem. 44 (2001) 4042
8. Sodeoka M., Sampe R., Kojima S., Baba Y., Usui T., Ueda K., and Osada H. J. Med. Chem. 44 (2001) 3216
9. Chen C., Liu Y.Z., Shia K.S., and Tseng H.Y. Bioorg. Med. Chem. Lett. 12 (2002) 2729
10. Wipf P., Hopkins C.R., Phillips E.O., and Lazo J.S. Tetrahedron 58 (2002) 6367
11. Brohm D., Philippe N., Metzger S., Bhargava A., Muller O., Lieb F., and Waldmann H. J. Am. Chem. Soc. 124 (2002) 13171
12. Sohn J., Kiburz B., Li Z., Deng L., Safi A., Pirrung M.C., and Rudolph J. J. Med. Chem. 46 (2003) 2580
13. Baurle S., Blume T., Gunther J., Henschel D., Hillig R.C., Husemann M., Mengel A., Parchmann C., Schmid E., and Skuballa W. Bioorg. Med. Chem. Lett. 14 (2004) 1673
14. Furstner A., Reinecke K., Prinz H., and Waldmann H. ChemBioChem 5 (2004) 1575
15. Contour-Galcera M.O., Lavergne O., Brezak M.C., Ducommun B., and Prevost G. Bioorg. Med. Chem. Lett. 14 (2004) 5809
16. Cao S., Foster C., Brisson M., Lazo J.S., and Kingston D.G. Bioorg. Med. Chem. 13 (2005) 999
17. Lavergne O., Fernandes A.C., Brehu L., Sidhu A., Brezak M.C., Prevost G., Ducommun B., and Contour-Galcera M.O. Bioorg. Med. Chem. Lett. 16 (2006) 171
18. Huang W., Li J., Zhang W., Zhou Y., Xie C., Luo Y., Li Y., Wang J., Li J., and Lu W. Bioorg. Med. Chem. Lett. 16 (2006) 1905
19. Kolb S., Mondesert O., Goddard M.L., Jullien D., Villoutreix B.O., Ducommun B., Garbay C., and Braud E. ChemMedChem 4 (2009) 633
20. Park H., Carr B.I., Li M., and Ham S.W. Bioorg. Med. Chem. Lett. 17 (2007) 2351
21. Brezak M.C., Quaranta M., Contour-Galcera M.O., Lavergne O., Mondesert O., Auvray P., Kasprzyk P.G., Prevost G.P., and Ducommun B. Mol. Cancer Ther. 4 (2005) 1378
22. Contour-Galcera M.O., Sidhu A., Prevost G., Bigg D., and Ducommun B. Pharmacol. Ther. 115 (2007) 1
23. Mustafa A., Zayed S.M.A.D., and Khattab S. J. Am. Chem. Soc. 78 (1956) 145
24. Ead H.A., Hassaneen H., Abdallah M., and Mousa H. Arch. Pharm. (Weinheim) 324 (1991) 35
25. Abdelhamid A.O. J. Chem. Res. (S) (1993) 208
26. Stepakov A.V., Molchanov A.P., and Kostikov R.R. Russ. J. Org. Chem. 41 (2005) 243
27. 2 under acidic condition to give ethyl diazoacetate 2a. Through converting corresponding carboxylic acids to acyl chlorides, then acylating diazomethane, compounds 2b-e were prepared. Mulzer J. In: Katritzky A.R., Meth-Cohn O., and Rees C.W. (Eds). Comprehensive Organic Functional Group Transformations (1995), Pergamon Press, Oxford pp 144 and 276
28. +) 497.33.
29. +) 503.28.
30. The reversible binding assay were carried out by preincubation 0.12 μM compound 118 with Cdc25, then dialyzed for indicated time for activity recovery.
31. Zhou Y.B., Feng X., Wang L.N., Du J.Q., Zhou Y.Y., Yu H.P., Zang Y., Li J.Y., and Li J. Acta Pharmacol. Sin. 30 (2009) 1359